Jubilant Life Sciences, an integrated pharma and life sciences company, witnessed a rise in share price on Tuesday after the company received final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally disintegrating tablets

The tablets are used for the acute treatment of migraine in adults and in pediatric patients.

Rizatriptan Benzoate tablets are the generic version of Maxalt-MLT orally disintegrating, 5 mg and 10 mg Tablets of Merck.

As on Jun. 30, 2015, the company had a total of 815 filings for formulations of which 389 have been approved in various regions globally.

Shares of Jubilant Life Sciences are trading at Rs 397.60, up Rs 9.3, or 2.40% at the Bombay Stock Exchange (BSE) on Tuesday at 12:46 p.m.

The scrip has touched an intra-day high of Rs 404.05 and low of Rs 384.10. The total volume of shares traded at the BSE is 303,357.